Business Wire

CA-AGENDIA

2.5.2022 23:54:08 CEST | Business Wire | Press release

Share
Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022

Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced it will present new data from ongoing clinical research evaluating its comprehensive genomic tests at the upcoming American Society of Clinical Oncology Annual Meeting (ASCO), taking place June 3-7, 2022 in Chicago, Illinois.

Data will highlight Agendia’s clinical focus on whole transcriptome analysis as well as breast cancer care for underserved populations, in addition to several sub-studies derived from the company’s FLEX Registry, the real-world, multicenter, prospective, observational breast cancer study. Two abstracts selected by ASCO for oral discussion will feature an investigation of the ImPrint genomic test, currently for research use only, from the I-SPY trial series and an analysis from FLEX of hormone receptor-positive breast cancer in Black women classified by BluePrint® .

The company believes the FLEX Registry’s approach to cancer research is accelerating impactful data generation, aimed at redefining cancer care. Its patient-centric design and national network of participating sites is backed by Agendia’s infrastructure, allowing its investigator-initiated sub-studies to produce important results that have the potential to drive science forward, like those being shared at ASCO 2022.

Following are details of the nine Agendia abstracts that have been accepted for poster discussion or poster sessions at the ASCO 2022 Annual Meeting:

Poster discussion sessions

  • The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2
    Authors: Kuilman, MM., et al.
    Presenter: Lorenza Mittempergher, PhD | Research and Development, Agendia NV
    Session: Breast Cancer – Local/Regional/Adjuvant
    Poster Discussion: Monday, June 6, 2022 | 1:15 PM-2:45 PM CDT
    Abstract #: 514
  • Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint
    Authors: Reid, S., et al.
    Presenter: Sonya A. Reid, MD, MPH | Vanderbilt University Medical Center
    Session: Breast Cancer – Local/Regional/Adjuvant
    Poster Discussion: Monday, June 6, 2022 | 1:15 PM-2:45 PM CDT
    Abstract #: 517
    Poster sessions
  • Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial
    Authors: Socoteanu, M., et al.
    Session: Breast Cancer – Local/Regional/Adjuvant
    Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    Abstract #: 556
  • Clinical implications for patients with discordant oncotype and MammaPrint results
    Authors: Socoteanu, M., et al.
    Session: Breast Cancer – Local/Regional/Adjuvant
    Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    Abstract #: 560
  • Investigation of a genomic signature for transcription factor MAF gene amplification and lack of bisphosphonate benefit in early breast cancer
    Authors: Nasrazadani, A., et al.
    Session: Breast Cancer – Local/Regional/Adjuvant
    Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    Abstract #: 559
  • Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy
    Authors: Chung, A., et al.
    Session: Breast Cancer – Local/Regional/Adjuvant
    Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    Abstract #: 585
  • Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 trial and FLEX Registry
    Authors: Cha, J., et al.
    Session: Breast Cancer – Local/Regional/Adjuvant
    Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    Abstract #: 592
  • FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data
    Authors: Ma, C., et al.
    Session: TBC
    Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    Abstract #: TPS612
  • Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study
    Authors: Sivapiragasam, A., et al.
    Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
    Session Date & Time: Sunday, June 5, 2022 | 8:00 AM-11:00 AM CDT
    Abstract #: 3134

Agendia will be sharing important updates on its Twitter , Facebook and LinkedIn pages throughout the conference. The event program can be found at the ASCO 2022 website.

About Agendia

Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.

MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of the biology underlying an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.

For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Freemarket and Axiym launch LIQUI-DT™ – real-time business access to primary-market USD₮ from Tether29.9.2026 08:00:00 CEST | Press release

Freemarket and Axiym today launched a world-first service that gives businesses 24/7 real-time access to freshly minted, primary-market USD₮ issued by Tether. LIQUI-DTTM gives businesses compliant access to primary market stablecoins inside a fully regulated payment ecosystem via Freemarket’s global payment network. In audited trials, clients have minted or burned more than $300 million to date. Institutional users and high-volume traders will benefit from superior price certainty and direct liquidity giving them budgetary control. As the USD₮ is minted directly in the primary market, treasury and compliance teams have clear provenance for internal reporting 1. The LIQUI-DT service works because while no single party owns the whole stack, it is integrated into the Freemarket network. The combination of Freemarket’s compliant fiat rails and payment network, Axiym’s liquidity engine and on-chain settlement layer and Tether’s primary market issuance creates a regulated payments network wi

Estonia and Owkin Partner to Advance Sovereign AI in Biology29.9.2026 08:00:00 CEST | Press release

Estonia, led by the National Applied Research Center Metrosert, and Owkin today announced a collaboration to advance sovereign AI in biological and health research, working with Metrosert, Estonia’s state-owned applied research organisation. The collaboration will evaluate how K Pro, Owkin’s AI scientist platform, can help approved researchers work with complex Estonian health data inside secure national infrastructure, enabling reproducible analysis, and faster generation of scientific insight while preserving data sovereignty. The first phase will focus on selected Estonian health-data cohorts, with Owkin and Metrosert also exploring high-value research areas including oncology, where linked clinical, molecular, imaging and treatment-outcome data could support future biomedical research. Estonia has built one of the world’s most advanced digital public infrastructures and holds population-scale health and biomedical data assets. The partnership will explore how these foundations can

Jumio Completes Worldwide Rollout of selfie.DONE™, Bringing Privacy-Focused Reusable Identity to EMEA29.9.2026 07:00:00 CEST | Press release

Selfie-first onboarding eliminates unnecessary ID scans for trusted users, backed by the global Jumio Identity Graph, consent-based privacy and real-time compliance Jumio, the leading provider of AI-powered identity intelligence, today announced the expansion of its reusable identity solution, selfie.DONE, across Europe, the Middle East, and Africa. This launch marks the final phase of Jumio’s selfie.DONE rollout, following successful launches in Latin America, North America, and Asia-Pacific — making true reusable identity available worldwide wherever Jumio operates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928989719/en/ In regulated EMEA markets, organizations face the dual challenge of eliminating onboarding friction while adhering to stringent privacy standards and regulatory frameworks, including GDPR, PSD2, AMLD, and other evolving regulatory compliance requirements. selfie.DONE addresses this challenge with a

Copeland to Showcase Solutions for Data Centers, Heat Pumps and Sustainable Refrigeration at Chillventa29.9.2026 07:00:00 CEST | Press release

Technologies designed to help customers improve efficiency, reduce emissions and address evolving cooling, heating and cold chain needs Copeland, a global leader in compression technologies and controls solutions, today announced its participation at Chillventa 2026, taking place Oct. 13-15 in Nuremberg, Germany. From growing data center cooling demands to increased adoption of heat pumps and natural refrigerants, customers across Europe are navigating rapid change. Copeland will showcase technologies designed to address the region's evolving heating, cooling and refrigeration requirements. As demand for energy-efficient cooling, electrified heating and sustainable industrial operations grows across Europe, Copeland continues to invest in the technologies, capabilities and partnerships needed to help customers navigate changing regulatory requirements and work toward their sustainability objectives. Copeland has made a series of strategic investments to support Europe's long-term energ

Lumo Art & Tech Festival Announces Full Programme, Featuring Björk29.9.2026 07:00:00 CEST | Press release

13–22 November 2026 Lumo Art & Tech festival, a new ten-day international festival exploring the intersection of art, technology and science, has announced its full programme for its inaugural edition in Oulu, Northern Finland, as part of the Oulu2026 European Capital of Culture year. Taking place across 16 cultural venues and outdoor locations, the festival brings together exhibitions, light and sound art, audiovisual performances, talks and professional events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928733910/en/ Björk. Credit: Vidar Logi A key highlight is an exhibition by Icelandic artist and musician Björk, opening on 13 November. Following its debut in Reykjavík, the exhibition brings three audiovisual installations to Oulu’s Pekuri Shopping Centre: Ancestress, Sorrowful Soil and Björk Orkestral. Björk will also perform a special DJ set at the new waterfront venue Tarkastamo on 15 November. The festival’s wi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye